ASP Isotopes Inc. has acquired Renergen, a South African helium company, for $161.8 million, enhancing its access to high-grade helium reserves and ensuring a stable supply amidst global shortages.
Information on the Target
A SP Isotopes Inc. (ASPI) has officially announced its acquisition of Renergen, a prominent South African company renowned for its substantial helium reserves. The acquisition, valued at $161.8 million, will provide ASPI with direct access to one of the highest-grade helium reserves globally, located in the Virginia Gas Project, where helium concentrations can reach up to 12%, significantly surpassing the global average of approximately 0.5%.
This strategic acquisition not only allows ASPI to expand its portfolio but also positions it to address the escalating global demand for helium, a vital non-renewable resource that is critical across various industries, including healthcare, semiconductor manufacturing, and aerospace.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in South Africa
The helium industry in South Africa is at a pivotal point, primarily due to the global decline in helium supply from traditional sources. As countries like the U.S. wind down their Federal Helium Reserve, South Africa
Similar Deals
Exxaro Resources Limited → Ntsimbintle Holdings Proprietary Limited and OMH (Mauritius) Corp
2025
EverSeed Energy Proprietary Limited → Exxaro FerroAlloys Proprietary Limited
2025
Exxaro Resources Limited → Ntsimbintle Holdings and OM Holdings
2025
Implats → Platinum Group Metals Ltd, Japan Oil, Gas and Metals National Corporation, Mnombo Wethu Consultants Pty Ltd
2017
Exxaro Resources Limited → Gouda Wind Farm and Sishen Solar Facility
2026
ASP Isotopes
invested in
Renergen
in 2025
in a Other deal
Disclosed details
Transaction Size: $162M
EBITDA: $300M
Enterprise Value: $162M
Equity Value: $107M
Multiples
EV/EBITDA: 0.5x